Pfizer, Moderna vaccines wouldn’t have got nod had they done phase three trials in second wave: Krishna Ella

Hyderabad-based Bharat Biotech, the manufacturer of COVID-19 Covaxin, said the efficacy of its vaccine would have been 85 per cent against the original strain of the virus.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *